BioInvent's Ovarian Cancer Treatment Combination Receives Fast Track Designation from US FDA

MT Newswires · 2d ago
06:03 AM EDT, 08/07/2026 (MT Newswires) -- BioInvent International (BINV.ST) received fast track designation from the US Food and Drug Administration for its BI-1808 antibody for the treatment of ovarian cancer in combination with pembrolizumab. The novel immune-modulatory antibodies discovery company said in a Friday release that the treatment combination produced a 24% confirmed overall response rate and a 56% disease control rate in interim phase 2a results.